Skip to main content
. Author manuscript; available in PMC: 2011 Feb 28.
Published in final edited form as: Ann Neurol. 2009 Jan;65(1):67–75. doi: 10.1002/ana.21536

Fig 1.

Fig 1

Prophylactic effect of C5 complement inhibitor (rEV576) in passive experimentally acquired myasthenia gravis (EAMG). Survival rate (A) and average clinical score (B) in surviving rats were examined in passively induced EAMG. Female Lewis rats matched for age and weight were injected with McAb3. Untreated animals (n = 7; gray lines) experienced development of severe weakness, and three rats died within 48 hours. EAMG rats treated with rEV576 (n = 6; black lines) were protected from mortality and showed only mild weakness with a low severity score (data expressed as mean score assessed every 12 hours).